GlobeNewsWire
18 Aug 2026, 12:53 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
AKTX-101 demonstrated anti-tumor activity in urothelial cancer models that were resistant to current first-generation TROP2-directed ADCs. — Proof-of-concept for overcoming ADC resistance addresses a major clinical unmet need and validates the company's unique payload platform.
+0.60Akari Therapeutics plans to initiate Phase 1 clinical development for AKTX-101 in mid-2027. — Provides a concrete timeline for the transition from preclinical to clinical stages, though the date is several years away.
+0.30The company is seeking strategic collaborations to expand the development of its proprietary PH1 RNA spliceosome modulating payload platform. — Potential for non-dilutive funding or partnership validation, though no specific partners are named.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company reported robust anti-tumor preclinical data for its AKTX-101 candidate, supporting its differentiated ADC strategy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Globe News Wire
6h ago
